BMS’ Azacitidine Receives NICE Recommendation for the Treatment of Acute Myeloid Leukaemia
Shots:
- The NICE has issued a FAD recommending azacitidine as a maintenance therapy in adult AML patients who achieved CR or complete remission with incomplete blood count recovery (CRi) after receiving induction therapy with/out consolidation treatment
- The NICE decision was based on the P-III (QUAZAR AML-001) study to evaluate azacitidine in adult patients with AML
- The results showed a significant OS and relapse-free survival benefit over PBO in patients with AML subtypes who were in remission after CT and ineligible for an HSCT, m-OS from the time of randomization was longer (24.7mos. vs 14.8mos.) & median relapse-free survival (10.2mos. and 4.8mos.), health-related QoL was maintained across both treatment arms
Ref: ecancer| Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
